Inspire Medical Systems Inc (INSP)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.77B
Last updated: Nov 17, 2026 at 11:06 AM ET
Inspire Medical Systems Inc (INSP) Stock Forecast
Analysts expect Inspire Medical Systems (INSP) to earn $1.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $855.42M. Of 18 analysts, 4 rate the stock Buy or Strong Buy, 11 Hold and 3 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 3.06, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 22% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 22.2% |
| Hold | 11 | 61.1% |
| Sell | 1 | 5.6% |
| Strong Sell | 2 | 11.1% |
- Consensus
- Hold
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 15.4% and revenue estimates rise 2.6%.
- Fiscal year ending Dec 31, 2026
- $1.30
- EPS consensus, revenue $855.42M
- Fiscal year ending Dec 31, 2027
- $1.50
- EPS consensus, revenue $877.76M
- Next report
- May 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.30 | $1.23 to $1.35 | 15 | $855.42M | $850.08M to $861.90M | 17 |
| Dec 31, 2027 | $1.50 | $1.36 to $1.70 | 15 | $877.76M | $860.88M to $908.40M | 17 |
Quarterly Estimates
The EPS consensus falls from $0.73 for the quarter ending Dec 31, 2026 to $0.13 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.73 | $0.33 to $0.96 | 19 | $247.50M | $225.40M to $258.30M | 18 |
| Mar 31, 2027 | $0.13 | -$0.13 to $0.34 | 10 | $192.40M | $184.84M to $200.30M | 10 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.0% from $1.25.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.30 | $1.25 | $1.25 | $1.25 | $1.25 | +4.3% |
| Fiscal year ending Dec 31, 2027 | $1.50 | $1.54 | $1.54 | $1.54 | $1.54 | -2.7% |
| Quarter ending Mar 31, 2027 | $0.13 | $0.15 | $0.15 | $0.15 | $0.15 | -16.1% |
Frequently Asked Questions About INSP
What is the INSP stock forecast?
Consensus analyst estimates put Inspire Medical Systems's EPS at $1.30 for the fiscal year ending Dec 31, 2026, on revenue of $855.42M. The consensus rating from 18 analysts is Hold.
How do analysts rate INSP stock?
Of 18 analysts covering Inspire Medical Systems, 0 rate it Strong Buy, 4 Buy, 11 Hold, 1 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from INSP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.30, with estimates from $1.23 to $1.35 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.50, with estimates from $1.36 to $1.70 from 15 analysts.
What revenue do analysts expect from Inspire Medical Systems next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $855.42M, with estimates from $850.08M to $861.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $877.76M, with estimates from $860.88M to $908.40M.
How many analysts cover INSP?
18 analysts rate Inspire Medical Systems stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts